

BrainStorm Cell Therapeutics Added to Russell Microcap® Index

HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 29, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap® Index. The Russell indexes are reconstituted on an annual basis, with this year's process having concluded on June 26. Information on the Russell Microcap® Index and the reconstitution process can be found on the FTSE Russell website (<http://www.russell.com/>).

"We are pleased to be added to the Russell Microcap® Index," said Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm. "Inclusion in this index should bring increased exposure in the investment community as well as increased liquidity in our shares, as we continue our development of NurOwn® as a treatment for debilitating neurodegenerative diseases."

FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Annual reconstitution of Russell indices captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000 Index and Russell Microcap® Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately \$5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Logo - <http://photos.prnewswire.com/prnh/20141006/150511>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-added-to-russell-microcap-index-300106024.html>

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media, Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460, info@brainstorm-cell.com; Investors, Michael Wood, LifeSci Advisors, LLC, 646-597-6983, mwood@lifesciadvisors.com

Additional assets available online:  [Photos \(1\)](#)

<https://ir.brainstorm-cell.com/2015-06-29-BrainStorm-Cell-Therapeutics-Added-to-Russell-Microcap-R-Index>